CLEC16A

Across TCGA pan-cancer cohorts, CLEC16A mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of CLEC16A’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where CLEC16A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CLEC16A is over-expressed in tumor, although a few such as LSCC and PDAC show the opposite, repressed pattern.

LUAD, LSCC, and PDAC are the cancer types where CLEC16A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLEC16A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	II,III,IV	+0.143	<.001	8	view →
LSCC	All	II,III,IV	−0.127	<.001	8	view →
PDAC	All	II,III,IV	−0.344	<.001	6	view →
COAD	Female	All	−0.194	.005	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

CLEC16A–LUAD

Open the LUAD breakdown →